Skip to main content

Table 1 Demographic data for Thal-HSCT patients by donor group: haploidentical and matched-donor

From: No differences in hemostatic and endothelial activations between haploidentical and matched-donor hematopoietic stem cell transplantation in thalassemia disease

  Type of donor P-value
Haploidentical
n = 14
Matched-donor
n = 9
Type of thalassemia, n (%) 0.295a
 HbE/β 13 (93) 7 (78)  
 β major 1 (7) 2 (22)  
Age at HSCT in years, median (range) 10.6 (2.7–18.9) 8.2 (3.8–20.2) 0.926b
Day after HSCT in days, median (range) 54 (15–331) 87 (35–296) 0.374b
Ferritin in ng/ml, median (IQR) 2972.6 3512.7 0.913b
Hepatomegaly, n (%) 5 (56) 6 (75) 0.147a
Classification, n (%)
 Age < 7 years, no hepatomegaly 0 (0) 0 (0)  
 Age > 7 years, no hepatomegaly 4 (44) 2 (25)  
 Age < 7 years, hepatomegaly 0 (0) 2 (25)  
 Age > 7 years, hepatomegaly 5 (56) 4 (50)  
Conditioning regimen, n (%)
 Bu + Cy   2 (22)  
 ATG + Flu + Bu 14 (100) 7 (78)  
Chimerism, n (%)    0.412a
 Complete donor 13 (93) 9 (100)  
 Mixed 1* (7)   
Veno-occlusive disease, n (%) 2 (14) 3 (33) 0.280a
Graft-versus-host disease, n (%)
 Acute GvHD    
 Grade I/II 7 (50) 2 (22) 0.171a
 Grade III/IV  0 (0)  1 (11)  
 Chronic GvHD 1 (7) 0 (0) 0.412a
Infection, n (%)
 Bacterial 3 (21)  0 (0) 0.136a
 Viral 7 (50) 3 (33) 0.431a
  1. IQR interquartile range, GvHD graft versus host disease
  2. Conditioning regimen: ATG Thymoglobulin, Bu busulfan, Cy Cyclophosphamide, Flu fludarabine
  3. *Donor chimerism 76.5%
  4. *All patients in the haploidentical HSCT group received pre-transplant immunosuppression (PTIS), 7 patients who were > 7 years old in the matched-donor HSCT group received PTIS (ref. 7) PTIS consisted of fludarabine 40 mg/m2/day and dexamethasone 25 mg/m2/day
  5. Statistical analysis performed using: a Chi-Square, b Bonferroni